Afficher la couverture 'First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) | Descourt, Renaud' en grand format
/5

0 avis

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Archive ouverte

Descourt, Renaud | Greillier, Laurent | Perol, Maurice | Ricordel, Charles | Auliac, Jean-Bernard | Falchero, Lionel | Gervais, Radj | Veillon, Rémi | Vieillot, Sabine | Guisier, Florian | Marcq, Marie | Justeau, Grégoire | Bigay-Game, Laurence | Bernardi, Marie | Fournel, Pierre | Doubre, Hélène | Pinsolle, Julian | Amrane, Karim | Chouaïd, Christos | Decroisette, Chantal

Edité par CCSD ; Springer Verlag -

International audience. Few real-world data are available in patients with advanced metastatic non-small cell lung cancer (NSCLC) treated with first-line immunotherapy, particularly in those with brain metastases at treatment initiation.

Consulter en ligne

Suggestions

Du même auteur

Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)

Archive ouverte | Decroisette, Chantal | CCSD

International audience. Outside clinical trials, few data are available on the effect of long-term first-line pembrolizumab in patients with advanced non–small-cell lung cancers with ≥50% of tumor cells expressing p...

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Archive ouverte | Doubre, Hélène | CCSD

International audience. BackgroundFew data are available on the impact of venous thrombotic events (VTE) in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy.MethodsThis is a se...

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study

Archive ouverte | Arpin, Dominique | CCSD

International audience. Background: Few data are available on programmed cell-death-protein-1-ligand-1 (PD-L1) expression on large-cell neuroendocrine carcinomas of the lung (LCNECs). We analyzed PD-L1 expression on...

Chargement des enrichissements...